Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Chief Business Officer

President and CEO

Chief Financial Officer

Chief Legal Officer

Chief Scientific Officer

Chief Development Officer

Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncol...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-22	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-02-22	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-02-22	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-22	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-22	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-22	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-02-01	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-01-29	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-01-29	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-01-23	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-01-23	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-01-22	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-01-22	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2023-12-26	Premium	sold	Premium	Premium	Premium	President and CEO
2023-12-21	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-21	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-21	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-12-21	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-12-18	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-12-18	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-18	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-18	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-12-12	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-12-12	Premium	sold	Premium	Premium	Premium	Chief Financial Officer

CGEM - Cullinan Management, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for CGEM